SweDeliver webinar: UV1: A Universal Therapeutic Cancer Vaccine

SweDeliver invites to webinar with focus on Ultimovacs' lead product candidate: UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

At this webinar we meet Dr. Espen Basmo Ellingsen, MD, PhD student and Scientific Advisor at Ultimovacs, a pharmaceutical company developing novel immunotherapies against cancer. Ultimovacs' lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden.

Events for Medicine and Pharmacy